Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Chotirat, Sadudee ^a   Thongnoppakhun, Wanna ^a   Promsuwicha, Orathai ^b   Boonthimat, Chetsada ^b   Auewarakul, Chirayu U ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Acute myeloid leukemia; Cooperative mutations; IDH1; IDH2; Isocitrate dehydrogenase; Metabolic enzymes; Normal karyotype

Indexed keywords

MITOCHONDRIAL ENZYME; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; NUCLEAR PROTEIN; NUCLEOPHOSMIN; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; AML 1 GENE; ARTICLE; CYTOGENETICS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; FEMALE; FLT 3 GENE; GENE; GENE MUTATION; HETEROZYGOSITY; HUMAN; IDH 1 GENE; IDH 2 GENE; INCIDENCE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NPM 1 GENE; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; OVERALL SURVIVAL; PML RARA GENE; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; SOMATIC MUTATION; THROMBOCYTE COUNT; GENETICS; GENOTYPE; KARYOTYPING; MIDDLE AGED; MUTATION;

ADOLESCENT; ADULT; AGED; FEMALE; GENOTYPE; HUMANS; ISOCITRATE DEHYDROGENASE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84857714230     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-5     Document Type: Article

References (46)

1. Acute myeloid leukaemia. Estey E, Dohner H, Lancet 2006 368 1894 1907 10.1016/S0140-6736(06)69780-8 17126723 (Pubitemid 44794525)
2. Cytogenetics in acute leukemia. Mrozek K, Heerema NA, Bloomfield CD, Blood Rev 2004 18 115 136 10.1016/S0268-960X(03)00040-7 15010150 (Pubitemid 38380667)
3. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. Takahashi S, J Hematol Oncol 2011 4 13 10.1186/1756-8722-4-13 21453545
4. Current findings for recurring mutations in acute myeloid leukemia. Takahashi S, J Hematol Oncol 2011 4 36 10.1186/1756-8722-4-36 21917154
5. Recurring mutations found by sequencing an acute myeloid leukemia genome. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, et al. N Engl J Med 2009 361 1058 1066 10.1056/NEJMoa0903840 19657110
6. Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation. Briere JJ, Favier J, Gimenez-Roqueplo AP, Rustin P, Am J Physiol Cell Physiol 2006 291 1114 C1120 10.1152/ajpcell.00216.2006 16760265 (Pubitemid 44878582)
7. Cancer as a metabolic disease. Seyfried TN, Shelton LM, Nutr Metab (Lond) 2010 7 7 10.1186/1743-7075-7-7
8. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. Nature 2009 462 739 744 10.1038/nature08617 19935646
9. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, et al. Science 2009 324 261 265 10.1126/science.1170944 19359588
10. Peroxisomal NADP-Dependent Isocitrate Dehydrogenase. Characterization and Activity Regulation during Natural Senescence. Corpas FJ, Barroso JB, Sandalio LM, Palma JM, Lupianez JA, del Rio LA, Plant Physiol 1999 121 921 928 10.1104/pp.121.3.921 10557241
11. IDH mutations in glioma and acute myeloid leukemia. Dang L, Jin S, Su SM, Trends Mol Med 2010 16 387 397 10.1016/j.molmed.2010.07.002 20692206
12. An integrated genomic analysis of human glioblastoma multiforme. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. Science 2008 321 1807 1812 10.1126/science.1164382 18772396
13. IDH1 and IDH2 mutations in gliomas. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. N Engl J Med 2009 360 765 773 10.1056/NEJMoa0808710 19228619
14. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, et al. Hum Mutat 2009 30 7 11 10.1002/humu.20937 19117336
15. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, et al. J Clin Oncol 2010 28 2348 2355 10.1200/JCO.2009.27.3730 20368543
16. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A, Leukemia 2010 24 1146 1151 10.1038/leu.2010.77 20410924
17. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, et al. Leukemia 2010 24 1094 1096 10.1038/leu.2010.52 20376084
18. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, et al. Blood 2010 115 2749 2754 10.1182/blood-2009-11-253070 20097881
19. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, et al. J Exp Med 2010 207 339 344 10.1084/jem.20092506 20142433
20. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, et al. Cancer Cell 2010 17 225 234 10.1016/j.ccr.2010.01.020 20171147
21. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, Ottmann O, Lubbert M, Heit W, Kanz L, et al. J Clin Oncol 2010 28 2356 2364 10.1200/JCO.2009.27.6899 20368538
22. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, et al. Leukemia 2010 24 909 913 10.1038/leu.2010.56 20376086
23. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Thol F, Damm F, Wagner K, Gohring G, Schlegelberger B, Hoelzer D, Lubbert M, Heit W, Kanz L, Schlimok G, et al. Blood 2010 116 614 616 10.1182/blood-2010-03-272146 20421455
24. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Lowenberg B, Valk PJ, Blood 2010 116 2122 2126 10.1182/blood-2009-11-250878 20538800
25. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, Spath D, Kayser S, Zucknick M, Gotze K, et al. J Clin Oncol 2010 28 3636 3643 10.1200/JCO.2010.28. 3762 20567020
26. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, Gale RE, Blood 2011 118 409 412 10.1182/blood-2010-12-322479 21596855
27. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T, Blood 2010 116 5486 5496 10.1182/blood-2010-02-267955 20805365
28. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Zou Y, Zeng Y, Zhang DF, Zou SH, Cheng YF, Yao YG, Biochem Biophys Res Commun 2010 402 378 383 10.1016/j.bbrc.2010.10.038 20946881
29. IDH1 and IDH2 mutations in pediatric acute leukemia. Andersson AK, Miller DW, Lynch JA, Lemoff AS, Cai Z, Pounds SB, Radtke I, Yan B, Schuetz JD, Rubnitz JE, et al. Leukemia 2011 25 1570 1577 10.1038/leu.2011.133 21647154
30. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R, Am J Clin Pathol 2011 135 35 45 10.1309/AJCPD7NR2RMNQDVF 21173122
31. Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. Lin J, Qian J, Yao DM, Li Y, Yang J, Chen Q, Chai HY, Xiao GF, Xu WR, Clin Biochem 2011 44 779 783 10.1016/j.clinbiochem.2011.04.014 21539821
32. Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Zhang Y, Wei H, Wang M, Huai L, Mi Y, Zhang Y, Lin DT, Liu B, Li W, Zhou C, et al. Leuk Res 2011 35 1301 1306 10.1016/j.leukres.2011.01.019 21316759
33. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. Cancer Cell 2010 18 553 567 10.1016/j.ccr.2010.11.015 21130701
34. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate- dependent dioxygenases. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu LX, et al. Cancer Cell 2011 19 17 30 10.1016/j.ccr.2010.12.014 21251613
35. Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. Auewarakul CU, Sritana N, Limwongse C, Thongnoppakhun W, Yenchitsomanus PT, Cancer Genet Cytogenet 2005 162 127 134 10.1016/j.cancergencyto.2005.03.011 16213360 (Pubitemid 41423469)
36. Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia. Auewarakul CU, Lauhakirti D, Tocharoentanaphol C, Eur J Haematol 2006 77 51 56 10.1111/j.1600-0609.2006. 00663.x 16573741 (Pubitemid 43876205)
37. AML1 mutation and its coexistence with different transcription factor gene families in de novo acute myeloid leukemia (AML): redundancy or synergism. Auewarakul CU, Leecharendkeat A, Tocharoentanaphol C, Promsuwicha O, Sritana N, Thongnoppakhun W, Haematologica 2007 92 861 862 10.3324/haematol.10914 17550866 (Pubitemid 350155319)
38. Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations. Boonthimat C, Thongnoppakhun W, Auewarakul CU, Haematologica 2008 93 1565 1569 10.3324/haematol.12937 18641025
39. Molecular characterization of PML-RAR fusion gene with acute promyelocytic leukemia (APL) by nested RT-PCR. Promsuwicha O, Thongnoppakhun W, Wongkhantee S, Tocharoentanaphol C, Auewarakul CU, Thai J Hematol Transf Med 2005 15 247 257
40. Nonparametric estimation from incomplete observations. Kaplan E, Meier P, J Am Stat Assoc 1958 53 457 481 10.2307/2281868
41. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, et al. J Clin Oncol 2010 28 3717 3723 10.1200/JCO.2010.28.2285 20625116
42. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A, Blood 2005 105 973 977 15388582 (Pubitemid 40170863)
43. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, Gohring G, Schumann C, Bug G, Ottmann O, et al. Haematologica 2010 95 1668 1674 10.3324/haematol.2010.025494 20494930
44. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. Green A, Beer P, N Engl J Med 2010 362 369 370 10.1056/NEJMc0910063 20112449
45. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Pardanani A, Patnaik MM, Lasho TL, Mai M, Knudson RA, Finke C, Ketterling RP, McClure RF, Tefferi A, Leukemia 2010 24 1370 1372 10.1038/leu.2010.98 20485375
46. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, et al. Leukemia 2010 24 1302 1309 10.1038/leu.2010.113 20508616